RITUXAN can be an important part of treatment for many NHL and CLL patients
RITUXAN is not chemotherapy. RITUXAN is a type of antibody therapy that targets and attaches to the CD20 protein found on the surface of both NHL and CLL cells and some healthy blood cells. Once attached to the CD20 protein, RITUXAN works in 2 different ways:
- By helping your own immune system destroy the cancer cells
- By destroying the cancer cells on its own
In addition, RITUXAN can also harm healthy cells in your body.
Your doctor may prescribe chemotherapy along with RITUXAN.
This depends on your type of cancer and the treatment you have had. During treatment, you may have a combination of side effects from both chemotherapy and RITUXAN. Follicular lymphoma patients whose initial treatment with RITUXAN + chemotherapy was successful and who use RITUXAN alone as maintenance therapy will not have side effects from chemotherapy because these patients will no longer be receiving chemotherapy. These patients, however, still may experience side effects from RITUXAN.
Tell your doctor about any side effect that bothers you or that does not go away.
Please see Important Safety Information for RITUXAN below.
RITUXAN is available by prescription only.